Literature DB >> 9203042

In vitro drug sensitivity testing of human testicular germ cell tumours with cytostatic drugs and interferon alpha-2b.

B Küpeli1, S Baltaci, M Beksac, O Süzer, S Küpeli, O Göğüs.   

Abstract

In spite of the significant advances in the chemotherapy of germ cell neoplasms, some patients do not achieve disease-free status and ultimately die from their diseases. Therefore, it is reasonable to select the best chemotherapeutic agents in these patients by in vitro drug sensitivity assay (IVDSA) in order to apply the most effective agent in case of resistance to primary chemotherapy. Fresh operative cells from 12 testicular germ cell tumours (TGCT) were cultured in vitro. Sensitivity of the tumour cells to interferon-alpha (IFN-alpha), cisplatin, mitomycin C, vinblastine, doxorubicin, etoposide, bleomycin, vincristine (VCR) were tested by a colorimetric assay using MTT. A preexposure viability over 75% was essential for IVDSA. Sensitivity was determined by a more than 50 +/- 2 SD% reduction from the control absorbance. All eight drugs in their high concentrations exhibited cell proliferation inhibition in 83.3 +/- 100% of TGCT. But in low concentrations efficacy of IFN and VCR were found to be lower than the others (33.3% and 58.3%, respectively). The results indicated that although TGCT are highly sensitive to various agents IVDSA may help to identify the effective agents which might be necessary for second line chemotherapy in a small percentage of patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9203042     DOI: 10.1007/bf02551421

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  14 in total

1.  The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors.

Authors:  R J Motzer; K Cooper; N L Geller; D F Bajorin; E Dmitrovsky; H Herr; M Morse; W Fair; P Sogani; P Russo
Journal:  Cancer       Date:  1990-12-15       Impact factor: 6.860

2.  A rapid drug sensitivity assay for neoplasmatic cells.

Authors:  M Beksac; E Kansu; A Kars; Z Ibrahimoglu; D Firat
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

Review 3.  Interferon alpha-2a and vinblastine in the treatment of metastatic renal carcinoma.

Authors:  M Rizzo; R Bartoletti; C Selli; A Sicignano; D Criscuolo
Journal:  Eur Urol       Date:  1989       Impact factor: 20.096

Review 4.  Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review.

Authors:  S Wadler; E L Schwartz
Journal:  Cancer Res       Date:  1990-06-15       Impact factor: 12.701

5.  Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide.

Authors:  P J Loehrer; R Lauer; B J Roth; S D Williams; L A Kalasinski; L H Einhorn
Journal:  Ann Intern Med       Date:  1988-10-01       Impact factor: 25.391

6.  Predictive value of the fluorescent cytoprint assay (FCA): a retrospective correlation study of in vitro chemosensitivity and individual responses to chemotherapy.

Authors:  L A Leone; P A Meitner; T J Myers; W R Grace; W H Gajewski; H J Fingert; B Rotman
Journal:  Cancer Invest       Date:  1991       Impact factor: 2.176

Review 7.  In vitro predictive testing: the sulfonamide era.

Authors:  D D Von Hoff
Journal:  Int J Cell Cloning       Date:  1987-05

8.  Effect of alpha-interferon alone and combined with other antineoplastic agents on renal cell carcinoma determined by the tetrazolium microculture assay.

Authors:  Y Homma; Y Aso
Journal:  Eur Urol       Date:  1994       Impact factor: 20.096

9.  Predictive factors for the histologic nature of residual tumor mass after chemotherapy in patients with advanced testicular cancer.

Authors:  H Matsuyama; N Yamamoto; J Sakatoku; A Suga; S Hayashida; Y Kamiryo; K Nagata; K Naito
Journal:  Urology       Date:  1994-09       Impact factor: 2.649

10.  Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide.

Authors:  S D Williams; R Birch; L H Einhorn; L Irwin; F A Greco; P J Loehrer
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.